Accuray (NASDAQ:ARAY – Get Free Report) is projected to release its earnings data before the market opens on Wednesday, January 29th. Analysts expect Accuray to post earnings of ($0.02) per share and revenue of $110,360.00 billion for the quarter. Accuray has set its FY 2025 guidance at EPS.Investors interested in registering for the company’s conference call can do so using this link.
Accuray (NASDAQ:ARAY – Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.04). The business had revenue of $101.55 million during the quarter, compared to the consensus estimate of $98.10 million. Accuray had a negative net margin of 3.72% and a negative return on equity of 36.93%. During the same quarter last year, the company earned ($0.03) earnings per share. On average, analysts expect Accuray to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Accuray Trading Down 0.4 %
ARAY opened at $2.28 on Monday. Accuray has a 12-month low of $1.40 and a 12-month high of $2.95. The company has a debt-to-equity ratio of 3.59, a current ratio of 1.63 and a quick ratio of 0.87. The stock has a market capitalization of $229.30 million, a PE ratio of -13.41 and a beta of 1.47. The firm’s fifty day moving average price is $2.04 and its 200 day moving average price is $1.95.
Analyst Ratings Changes
Get Our Latest Stock Analysis on ARAY
About Accuray
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.
Read More
- Five stocks we like better than Accuray
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- MP Materials: Rare Earth Elements Powering the EV Boom
- Most active stocks: Dollar volume vs share volume
- Verizon’s Turnaround Gains Traction: New Highs Are Likely in 2025
- Are Penny Stocks a Good Fit for Your Portfolio?
- Bloom Energy: Powering the Future With Decentralized Energy
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.